Polyiclc
Stage III Lung Cancer AJCC v8
Fred Hutchinson Cancer CenterPhase 1/2Active
CCC
49/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 81/ 100
Competitive context
22 Active assets in the Stage III Lung Cancer AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Recombinant Human EGF-rP64K Roswell Park Cancer Institute | Phase 2 | BB |
Sotorasib National Cancer Institute (NCI) | Phase 2 | BB |
Montanide Isa 51 Roswell Park Cancer Institute | Phase 2 | B |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
Niraparib M.D. Anderson Cancer Center | Phase 2 | B |
View all 28 →
Same molecule, other indications
Polyiclc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →